A recent analysis suggests Johnson & Johnson's celebrated dividend growth streak could face pressure. This pressure stems from the planned spinoff of its DePuy Synthes orthopedics division. The separation aligns with J&J's strategy to concentrate on higher-growth segments, including pharmaceuticals and medical technology.
J&J announced the plan in October 2025. The company targets completion by mid-to-late 2027. DePuy Synthes generates over $9 billion in annual sales.
Its scale has prompted questions regarding the dividend's future. J&J's leadership has addressed these concerns. Following the announcement, the company's CFO stated no expected change to the dividend policy.